WO2022107084A1 - Pharmaceutical compositions for use in the management and treatment of pain - Google Patents
Pharmaceutical compositions for use in the management and treatment of pain Download PDFInfo
- Publication number
- WO2022107084A1 WO2022107084A1 PCT/IB2021/060776 IB2021060776W WO2022107084A1 WO 2022107084 A1 WO2022107084 A1 WO 2022107084A1 IB 2021060776 W IB2021060776 W IB 2021060776W WO 2022107084 A1 WO2022107084 A1 WO 2022107084A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pain
- bupivacaine
- pharmaceutical composition
- glyceryl
- formulated
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 118
- 230000036407 pain Effects 0.000 title claims abstract description 103
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 54
- 229960003150 bupivacaine Drugs 0.000 claims abstract description 83
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims abstract description 79
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims abstract description 30
- HEJZJSIRBLOWPD-WCWDXBQESA-N didodecyl (e)-but-2-enedioate Chemical compound CCCCCCCCCCCCOC(=O)\C=C\C(=O)OCCCCCCCCCCCC HEJZJSIRBLOWPD-WCWDXBQESA-N 0.000 claims abstract description 18
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 14
- 208000001294 Nociceptive Pain Diseases 0.000 claims abstract description 13
- 208000004296 neuralgia Diseases 0.000 claims abstract description 13
- 208000021722 neuropathic pain Diseases 0.000 claims abstract description 13
- 208000000094 Chronic Pain Diseases 0.000 claims abstract description 8
- JBJMZCVEBLDYCA-UHFFFAOYSA-N didodecyl butanedioate Chemical compound CCCCCCCCCCCCOC(=O)CCC(=O)OCCCCCCCCCCCC JBJMZCVEBLDYCA-UHFFFAOYSA-N 0.000 claims abstract description 7
- KWABLUYIOFEZOY-UHFFFAOYSA-N dioctyl butanedioate Chemical compound CCCCCCCCOC(=O)CCC(=O)OCCCCCCCC KWABLUYIOFEZOY-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 142
- 238000009472 formulation Methods 0.000 claims description 79
- 239000007937 lozenge Substances 0.000 claims description 60
- 239000007921 spray Substances 0.000 claims description 44
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 239000003589 local anesthetic agent Substances 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 20
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 19
- 238000013268 sustained release Methods 0.000 claims description 19
- 239000012730 sustained-release form Substances 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 18
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 18
- 239000003755 preservative agent Substances 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- 229920000642 polymer Polymers 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
- 229930195725 Mannitol Natural products 0.000 claims description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 15
- 239000000594 mannitol Substances 0.000 claims description 15
- 235000010355 mannitol Nutrition 0.000 claims description 15
- 229960001855 mannitol Drugs 0.000 claims description 15
- 201000001119 neuropathy Diseases 0.000 claims description 14
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 14
- 239000004094 surface-active agent Substances 0.000 claims description 13
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 13
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 12
- 230000007823 neuropathy Effects 0.000 claims description 12
- 239000008213 purified water Substances 0.000 claims description 12
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 11
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 11
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 11
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 11
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 11
- 239000007884 disintegrant Substances 0.000 claims description 11
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 11
- 229940069328 povidone Drugs 0.000 claims description 11
- 239000000811 xylitol Substances 0.000 claims description 11
- 235000010447 xylitol Nutrition 0.000 claims description 11
- 229960002675 xylitol Drugs 0.000 claims description 11
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 11
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims description 10
- 229960002303 citric acid monohydrate Drugs 0.000 claims description 10
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 10
- 239000000314 lubricant Substances 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 239000007967 peppermint flavor Substances 0.000 claims description 10
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 9
- 208000005298 acute pain Diseases 0.000 claims description 9
- 230000002335 preservative effect Effects 0.000 claims description 9
- 229940049703 saccharin sodium dihydrate Drugs 0.000 claims description 9
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 9
- 235000010234 sodium benzoate Nutrition 0.000 claims description 9
- 239000004299 sodium benzoate Substances 0.000 claims description 9
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 9
- 239000011230 binding agent Substances 0.000 claims description 8
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 229920003081 Povidone K 30 Polymers 0.000 claims description 7
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 239000006189 buccal tablet Substances 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 235000013355 food flavoring agent Nutrition 0.000 claims description 6
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 6
- 230000003232 mucoadhesive effect Effects 0.000 claims description 6
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 5
- 201000010927 Mucositis Diseases 0.000 claims description 5
- 239000007910 chewable tablet Substances 0.000 claims description 5
- 208000025865 Ulcer Diseases 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 239000006184 cosolvent Substances 0.000 claims description 4
- 208000003265 stomatitis Diseases 0.000 claims description 4
- 239000006068 taste-masking agent Substances 0.000 claims description 4
- 206010058019 Cancer Pain Diseases 0.000 claims description 3
- 208000010201 Exanthema Diseases 0.000 claims description 3
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims description 3
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 3
- 230000003444 anaesthetic effect Effects 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 239000007919 dispersible tablet Substances 0.000 claims description 3
- 201000005884 exanthem Diseases 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 206010037844 rash Diseases 0.000 claims description 3
- 229940041677 topical spray Drugs 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000008765 Sciatica Diseases 0.000 claims description 2
- 206010053692 Wound complication Diseases 0.000 claims description 2
- 229940046011 buccal tablet Drugs 0.000 claims description 2
- 229940068682 chewable tablet Drugs 0.000 claims description 2
- 238000013265 extended release Methods 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 229940100629 oral lozenge Drugs 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 206010006002 Bone pain Diseases 0.000 claims 1
- 206010047476 Viral rash Diseases 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 abstract description 18
- 230000035807 sensation Effects 0.000 abstract description 10
- 150000001875 compounds Chemical class 0.000 description 56
- -1 delivery methods Substances 0.000 description 26
- 239000010408 film Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 239000004480 active ingredient Substances 0.000 description 18
- 239000000463 material Substances 0.000 description 14
- 229940050411 fumarate Drugs 0.000 description 12
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- 206010029240 Neuritis Diseases 0.000 description 10
- 238000005469 granulation Methods 0.000 description 10
- 230000003179 granulation Effects 0.000 description 10
- 238000007726 management method Methods 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 235000019615 sensations Nutrition 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 230000006835 compression Effects 0.000 description 8
- 238000007906 compression Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 210000000214 mouth Anatomy 0.000 description 8
- 150000005846 sugar alcohols Polymers 0.000 description 8
- 208000001640 Fibromyalgia Diseases 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 206010003074 arachnoiditis Diseases 0.000 description 6
- 238000013329 compounding Methods 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 238000012377 drug delivery Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 235000021588 free fatty acids Nutrition 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229960004063 propylene glycol Drugs 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- 208000005198 spinal stenosis Diseases 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 206010036105 Polyneuropathy Diseases 0.000 description 5
- 229920002675 Polyoxyl Polymers 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 229960004288 levobupivacaine Drugs 0.000 description 5
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 229920001983 poloxamer Polymers 0.000 description 5
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- 208000023095 Autosomal dominant epidermolytic ichthyosis Diseases 0.000 description 4
- 206010064012 Central pain syndrome Diseases 0.000 description 4
- 206010008723 Chondrodystrophy Diseases 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 4
- 208000007465 Giant cell arteritis Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 206010043101 Talipes Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 201000001981 dermatomyositis Diseases 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 208000033286 epidermolytic ichthyosis Diseases 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 229960002920 sorbitol Drugs 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 201000006361 tethered spinal cord syndrome Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 3
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000006373 Bell palsy Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 3
- 208000000088 Enchondromatosis Diseases 0.000 description 3
- 201000009040 Epidermolytic Hyperkeratosis Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000007514 Herpes zoster Diseases 0.000 description 3
- 208000004286 Osteochondrodysplasias Diseases 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 229920002367 Polyisobutene Polymers 0.000 description 3
- 229920001710 Polyorthoester Polymers 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000000227 bioadhesive Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000007580 dry-mixing Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 210000000256 facial nerve Anatomy 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 235000013928 guanylic acid Nutrition 0.000 description 3
- 239000004226 guanylic acid Substances 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 230000001969 hypertrophic effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 238000005461 lubrication Methods 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 201000005518 mononeuropathy Diseases 0.000 description 3
- 235000013923 monosodium glutamate Nutrition 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 210000000929 nociceptor Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 235000010603 pastilles Nutrition 0.000 description 3
- 239000003961 penetration enhancing agent Substances 0.000 description 3
- 239000002745 poly(ortho ester) Substances 0.000 description 3
- 208000019629 polyneuritis Diseases 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 229960001866 silicon dioxide Drugs 0.000 description 3
- 238000004513 sizing Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 206010043207 temporal arteritis Diseases 0.000 description 3
- 150000003505 terpenes Chemical class 0.000 description 3
- 206010044652 trigeminal neuralgia Diseases 0.000 description 3
- 208000009935 visceral pain Diseases 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 2
- 208000018126 Adrenomyeloneuropathy Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 201000006390 Brachial Plexus Neuritis Diseases 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- AANLCWYVVNBGEE-IDIVVRGQSA-L Disodium inosinate Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 AANLCWYVVNBGEE-IDIVVRGQSA-L 0.000 description 2
- 208000004067 Flatfoot Diseases 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- 206010025219 Lymphangioma Diseases 0.000 description 2
- 208000003452 Multiple Hereditary Exostoses Diseases 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 206010029174 Nerve compression Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 208000004983 Phantom Limb Diseases 0.000 description 2
- 206010056238 Phantom pain Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 206010037779 Radiculopathy Diseases 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000008919 achondroplasia Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 235000019568 aromas Nutrition 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000006431 brachial plexus neuropathy Diseases 0.000 description 2
- 239000004196 calcium 5'-ribonucleotide Substances 0.000 description 2
- 235000013894 calcium 5'-ribonucleotide Nutrition 0.000 description 2
- 235000013921 calcium diglutamate Nutrition 0.000 description 2
- 239000004221 calcium diglutamate Substances 0.000 description 2
- 235000013900 calcium guanylate Nutrition 0.000 description 2
- 239000004244 calcium guanylate Substances 0.000 description 2
- 235000013893 calcium inosinate Nutrition 0.000 description 2
- 239000004197 calcium inosinate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 208000014884 cartilage development disease Diseases 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000001020 chondrodysplasia punctata Diseases 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 2
- WFPZPJSADLPSON-UHFFFAOYSA-N dinitrogen tetraoxide Chemical compound [O-][N+](=O)[N+]([O-])=O WFPZPJSADLPSON-UHFFFAOYSA-N 0.000 description 2
- 235000013898 dipotassium guanylate Nutrition 0.000 description 2
- 239000004192 dipotassium guanylate Substances 0.000 description 2
- 235000013892 dipotassium inosinate Nutrition 0.000 description 2
- 239000004195 dipotassium inosinate Substances 0.000 description 2
- PVBRXXAAPNGWGE-LGVAUZIVSA-L disodium 5'-guanylate Chemical compound [Na+].[Na+].C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@H]1O PVBRXXAAPNGWGE-LGVAUZIVSA-L 0.000 description 2
- 239000004193 disodium 5'-ribonucleotide Substances 0.000 description 2
- 235000013888 disodium 5'-ribonucleotide Nutrition 0.000 description 2
- 235000013896 disodium guanylate Nutrition 0.000 description 2
- 239000004198 disodium guanylate Substances 0.000 description 2
- 235000013890 disodium inosinate Nutrition 0.000 description 2
- 239000004194 disodium inosinate Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- ZDPUTNZENXVHJC-UUOKFMHZSA-N guanosine 3'-monophosphate Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H]1O ZDPUTNZENXVHJC-UUOKFMHZSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000002390 hyperplastic effect Effects 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000013902 inosinic acid Nutrition 0.000 description 2
- 239000004245 inosinic acid Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940033355 lauric acid Drugs 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 206010025005 lumbar spinal stenosis Diseases 0.000 description 2
- 235000013918 magnesium diglutamate Nutrition 0.000 description 2
- 239000004240 magnesium diglutamate Substances 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 235000013919 monopotassium glutamate Nutrition 0.000 description 2
- 239000004239 monopotassium glutamate Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 201000010193 neural tube defect Diseases 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000000668 oral spray Substances 0.000 description 2
- 229940041678 oral spray Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229920001084 poly(chloroprene) Polymers 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000007824 polyneuropathy Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- 239000000955 prescription drug Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229960003885 sodium benzoate Drugs 0.000 description 2
- 210000001032 spinal nerve Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000001797 sucrose acetate isobutyrate Substances 0.000 description 2
- 235000010983 sucrose acetate isobutyrate Nutrition 0.000 description 2
- UVGUPMLLGBCFEJ-SWTLDUCYSA-N sucrose acetate isobutyrate Chemical compound CC(C)C(=O)O[C@H]1[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](COC(C)=O)O1 UVGUPMLLGBCFEJ-SWTLDUCYSA-N 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 1
- KAKVFSYQVNHFBS-UHFFFAOYSA-N (5-hydroxycyclopenten-1-yl)-phenylmethanone Chemical compound OC1CCC=C1C(=O)C1=CC=CC=C1 KAKVFSYQVNHFBS-UHFFFAOYSA-N 0.000 description 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- VIAMIUDTTIDZCA-TYYBGVCCSA-N (e)-but-2-enedioic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)\C=C\C(O)=O VIAMIUDTTIDZCA-TYYBGVCCSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- LNKQQZFLNUVWQQ-UHFFFAOYSA-N 1-chloro-2,2-bis(4'-chlorophenyl)ethylene Chemical compound C=1C=C(Cl)C=CC=1C(=CCl)C1=CC=C(Cl)C=C1 LNKQQZFLNUVWQQ-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- TVVNZBSLUREFJN-UHFFFAOYSA-N 2-(4-chlorophenyl)sulfanyl-5-nitrobenzaldehyde Chemical compound O=CC1=CC([N+](=O)[O-])=CC=C1SC1=CC=C(Cl)C=C1 TVVNZBSLUREFJN-UHFFFAOYSA-N 0.000 description 1
- CXIISRLRZRAKST-UHFFFAOYSA-N 29‐(4‐nonylphenoxy)‐3,6,9,12,15,18,21,24,27‐ nonaoxanonacosan‐1‐ol Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 CXIISRLRZRAKST-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 208000005452 Acute intermittent porphyria Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 1
- 241000790908 Arachnitis Species 0.000 description 1
- 208000008037 Arthrogryposis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 208000023665 Barrett oesophagus Diseases 0.000 description 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 206010050217 Cervical radiculopathy Diseases 0.000 description 1
- 206010008313 Cervical spinal stenosis Diseases 0.000 description 1
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 208000004960 Congenital Ichthyosiform Erythroderma Diseases 0.000 description 1
- 208000030060 Congenital non-bullous ichthyosiform erythroderma Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000002650 Ellis-van Creveld syndrome Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 206010053177 Epidermolysis Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 208000002100 Equinus Deformity Diseases 0.000 description 1
- 208000025127 Erdheim-Chester disease Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010061159 Foot deformity Diseases 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Natural products CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 208000012528 Juvenile dermatomyositis Diseases 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000007914 Labor Pain Diseases 0.000 description 1
- 208000035945 Labour pain Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 208000027414 Legg-Calve-Perthes disease Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 206010024227 Lepromatous leprosy Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010050219 Lumbar radiculopathy Diseases 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 206010027910 Mononeuritis Diseases 0.000 description 1
- 206010027918 Mononeuropathy multiplex Diseases 0.000 description 1
- 206010028095 Mucopolysaccharidosis IV Diseases 0.000 description 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033128 Multiple osteochondromas Diseases 0.000 description 1
- 206010028665 Myxoedema Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 206010029229 Neuralgic amyotrophy Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 101150026239 PDPN gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 229920002614 Polyether block amide Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 206010036182 Porphyria acute Diseases 0.000 description 1
- 208000033141 Porphyria variegata Diseases 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 241000611831 Prevotella sp. Species 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 102100029028 Protoporphyrinogen oxidase Human genes 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037751 Radial nerve palsy Diseases 0.000 description 1
- 206010059604 Radicular pain Diseases 0.000 description 1
- 206010037778 Radiculitis brachial Diseases 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001486845 Scardovia Species 0.000 description 1
- 206010040744 Sinus headache Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000010261 Small Fiber Neuropathy Diseases 0.000 description 1
- 206010073928 Small fibre neuropathy Diseases 0.000 description 1
- 101710172814 Sodium channel protein Proteins 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 206010041603 Spinal vessel congenital anomaly Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- QFVOYBUQQBFCRH-UHFFFAOYSA-N Steviol Natural products C1CC2(C3)CC(=C)C3(O)CCC2C2(C)C1C(C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-UHFFFAOYSA-N 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194026 Streptococcus gordonii Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 201000010814 Synostosis Diseases 0.000 description 1
- 206010042928 Syringomyelia Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000024337 Talipes equinovarus Diseases 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 206010066334 Tethered cord syndrome Diseases 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241001227561 Valgus Species 0.000 description 1
- 201000011053 Variegate Porphyria Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1
- 208000024066 X-linked chondrodysplasia punctata Diseases 0.000 description 1
- 208000002522 X-linked chondrodysplasia punctata 1 Diseases 0.000 description 1
- 208000032810 X-linked dominant chondrodysplasia punctata Diseases 0.000 description 1
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 208000005065 achondrogenesis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000030597 adult Refsum disease Diseases 0.000 description 1
- 201000010411 adult dermatomyositis Diseases 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000018028 athetoid cerebral palsy Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- DAMJCWMGELCIMI-UHFFFAOYSA-N benzyl n-(2-oxopyrrolidin-3-yl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1CCNC1=O DAMJCWMGELCIMI-UHFFFAOYSA-N 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000002006 bullous congenital ichthyosiform erythroderma Diseases 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- WKZFQFQFYZJKPR-UHFFFAOYSA-N butanedioic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)CCC(O)=O WKZFQFQFYZJKPR-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- KAFMRSAFJZENBN-GWTDSMLYSA-L calcium guanylate Chemical compound [Ca+2].C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@H]1O KAFMRSAFJZENBN-GWTDSMLYSA-L 0.000 description 1
- ZLHWLLPKQPKYJD-MCDZGGTQSA-L calcium inosinate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 ZLHWLLPKQPKYJD-MCDZGGTQSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- UMVAYAXXQSFULN-QHTZZOMLSA-L calcium;(2s)-2-aminopentanedioate;hydron Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CCC(O)=O.[O-]C(=O)[C@@H](N)CCC(O)=O UMVAYAXXQSFULN-QHTZZOMLSA-L 0.000 description 1
- LNMAXKMUGYXKPJ-UHFFFAOYSA-L calcium;1,1-dioxo-1,2-benzothiazol-2-id-3-one Chemical compound [Ca+2].C1=CC=C2C([O-])=NS(=O)(=O)C2=C1.C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 LNMAXKMUGYXKPJ-UHFFFAOYSA-L 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001768 cations Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 201000002866 cervical dystonia Diseases 0.000 description 1
- 201000010415 childhood type dermatomyositis Diseases 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 201000011228 clubfoot Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 201000008230 cutaneous porphyria Diseases 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- PLMFYJJFUUUCRZ-UHFFFAOYSA-M decyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)C PLMFYJJFUUUCRZ-UHFFFAOYSA-M 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 201000001727 diffuse idiopathic skeletal hyperostosis Diseases 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- BCQFRUIIFOQGFI-LGVAUZIVSA-L dipotassium guanylate Chemical compound [K+].[K+].C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@H]1O BCQFRUIIFOQGFI-LGVAUZIVSA-L 0.000 description 1
- DLDSRSUKRMPQKB-IDIVVRGQSA-L dipotassium;[(2r,3s,4r,5r)-3,4-dihydroxy-5-(6-oxo-3h-purin-9-yl)oxolan-2-yl]methyl phosphate Chemical compound [K+].[K+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 DLDSRSUKRMPQKB-IDIVVRGQSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- XJCRCPKBJWRZAX-UHFFFAOYSA-L disodium;dibenzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 XJCRCPKBJWRZAX-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- TWFQJFPTTMIETC-UHFFFAOYSA-N dodecan-1-amine;hydron;chloride Chemical compound [Cl-].CCCCCCCCCCCC[NH3+] TWFQJFPTTMIETC-UHFFFAOYSA-N 0.000 description 1
- XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000027721 electron transport chain Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 201000011384 erythromelalgia Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 229940093503 ethyl maltol Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 208000034672 familial lumbar stenosis Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 206010049444 fibromatosis Diseases 0.000 description 1
- 201000010103 fibrous dysplasia Diseases 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 201000005298 gastrointestinal allergy Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000004247 glycine and its sodium salt Substances 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000010903 hereditary multiple osteochondromas Diseases 0.000 description 1
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 208000017326 inherited epidermolysis bullosa Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 229940028843 inosinic acid Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229960002479 isosorbide Drugs 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000026662 macrocystic lymphatic malformation Diseases 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- MYUGVHJLXONYNC-UHFFFAOYSA-L magnesium diglutamate Chemical compound [Mg+2].OC(=O)C(N)CCC([O-])=O.OC(=O)C(N)CCC([O-])=O MYUGVHJLXONYNC-UHFFFAOYSA-L 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 1
- 229940073769 methyl oleate Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 201000002003 mononeuritis multiplex Diseases 0.000 description 1
- 208000013734 mononeuritis simplex Diseases 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 208000008084 monostotic fibrous dysplasia Diseases 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 208000010978 mucopolysaccharidosis type 4 Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000003786 myxedema Diseases 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 229940073555 nonoxynol-10 Drugs 0.000 description 1
- 229940073554 nonoxynol-30 Drugs 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229940052264 other local anesthetics in atc Drugs 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- DYNKRGCMLGUEMN-UHFFFAOYSA-N parasorbic acid Natural products CC1CC=CC(=O)O1 DYNKRGCMLGUEMN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 208000001061 polyostotic fibrous dysplasia Diseases 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 208000000813 polyradiculoneuropathy Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229940096992 potassium oleate Drugs 0.000 description 1
- HQEROMHPIOLGCB-DFWYDOINSA-M potassium;(2s)-2-aminopentanedioate;hydron Chemical compound [K+].[O-]C(=O)[C@@H](N)CCC(O)=O HQEROMHPIOLGCB-DFWYDOINSA-M 0.000 description 1
- MLICVSDCCDDWMD-KVVVOXFISA-M potassium;(z)-octadec-9-enoate Chemical compound [K+].CCCCCCCC\C=C/CCCCCCCC([O-])=O MLICVSDCCDDWMD-KVVVOXFISA-M 0.000 description 1
- 208000017692 primary erythermalgia Diseases 0.000 description 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 208000009873 radial neuropathy Diseases 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 208000000029 referred pain Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- AIMUHNZKNFEZSN-UHFFFAOYSA-M sodium;decane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCS([O-])(=O)=O AIMUHNZKNFEZSN-UHFFFAOYSA-M 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 208000023531 spina bifida aperta Diseases 0.000 description 1
- 208000014485 spinal arachnoiditis Diseases 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QFVOYBUQQBFCRH-VQSWZGCSSA-N steviol Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)CC1)C[C@H]2[C@@]2(C)[C@H]1[C@](C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-VQSWZGCSSA-N 0.000 description 1
- 229940032084 steviol Drugs 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- CEYYIKYYFSTQRU-UHFFFAOYSA-M trimethyl(tetradecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)C CEYYIKYYFSTQRU-UHFFFAOYSA-M 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
Definitions
- the present invention discloses pharmaceutical compositions for treating pain in general. More particularly, this invention relates to pharmaceutical compositions for the treatment and management of pain broadly caused by tissue damage also called nociceptive pain and nerve damage also called neuropathic pain or central sensation or generalized pain or a mixed type of pain.
- Pain is a general term that describes uncomfortable sensations in the body. It results from activation of the nervous system. Pain may be sharp or dull or it may be intermittent, or it may be constant. Pain in general is classified into acute and chronic pain. Acute pain is intense and shortlived and can be of different types such as somatic pain, visceral pain and referred pain. While chronic pain is more server than acute pain, often with no cure. It can also be either continuous, or intermittent.
- Nociceptive pain is the most common type of pain. It can be either acute or chronic. It’s caused by stimulation of nociceptors, which are pain receptors for tissue injury found throughout your body, especially in your skin and internal organs. When injured they send electrical signals to the brain, causing pain. The visceral pain results from injuries or damage to the internal organs. It’s often not easy to pinpoint the exact location of pain. The somatic pain results from stimulation of the pain receptors in the tissues such as skin, muscles, joints, connective tissues, and bones.
- the neuropathic pain results from damage to or dysfunction of the nervous system.
- Neuropathic pain can be due to diabetic conditions, infections, facial nerve problems, such as Bell’s palsy, spinal nerve inflammation or compression, shingles, central nervous system disorders, such as multiple sclerosis or Parkinson’s disease and accidents.
- Pain can be treated using pain relief medication or by treating the underlying health issue. Different type of analgesics is used for pain management. Acetaminophen is commonly used analgesic as the over-the-counter and prescription drugs for treating moderate to severe pain. Other local anesthetics includes lidocaine, mepivacaine, ropivacaine and other which have local and systemic toxicity.
- Nonsteroidal anti-inflammatory drugs are another type of analgesic commonly used in treating minor acute pains.
- Opioids is a prescription drug for the most extreme acute pains, due to burns, cancer, surgery and bone fractures. Opioids are highly addictive and lose their effectiveness over time.
- PCT/IB 2017/052247 discloses compositions and methods for the treatment of chronic pain. The content of which are incorporated in its entirety herein by reference. However, IA PCT/IB 2017/052247 fails to disclose the pharmaceutical compositions, methods of preparation, various dosage forms, delivery methods, formulation and compositions for management of pain in various disease conditions.
- the present invention provides pharmaceutical compositions or formulations and methods for improving pain relief by administering local anesthetic formulation to the site for the treatment of acute or chronic pain, neuropathic pain or nociceptive pain or central sensation or generalized pain or a mixed type of pain.
- the present invention provides pharmaceutical compositions comprising local anesthetic or a derivative or a pharmaceutically active salt thereof.
- the local anesthetic, pharmaceutically active salt, derivatives or a mixture thereof examples include salts, derivatives or prodrugs of levo and dextro enantiomer of bupivacaine collectively called the compounds of bupivacaine of active ingredients.
- Levobupivacaine is the (S)-(-)-enantiomer of bupivacaine, with a longer duration of action and producing less vasodilation.
- Levobupivacaine or its derivative and any pharmaceutically active salts thereof are included within the scope of the present invention.
- the compounds of bupivacaine salt forms or a mixture of anion and cation forms containing bupivacaine (the active ingredient) and fatty acid derivative of glycerol fumarate or succinate as per the present invention is selected from the formulas I [bupivacaine glyceryl dilauryl succinate]or formula II [bupivacaine glyceryl dilauryl fumarate] or formula III [bupivacaine glyceryl dicapryl fumarate] or formula IV [bupivacaine glyceryl dicapryl succinate] .
- the pharmaceutical composition may comprise of formula I or formula II or formula III or formula IV along with one or more pharmaceutically acceptable excipients. Further discloses the method of preparing such compositions and its use in the pain management and treatment.
- the present invention also discloses the suitable dosage forms comprising therapeutically effective amount of compound of Formula I or Formula II or Formula III or Formula IV for treatment of pain which may be administered locally, topically, parenterally, or by infusion and/or orally.
- the present invention provides solid and liquid formulations of the pharmaceutical composition comprising compounds of Formula I or Formula II or Formula
- the present invention provides easy, convenient and patient friendly drug delivery system with better bio availability and long-lasting effect for treatment of pain.
- oral formulation IV are formulated for oral administration such as chewable tablets, buccal tablets, chewing gum, patches, tablets, cachets, lozenges, powder-based lozenges, syrup-based lozenges, granulated lozenges, pastilles and dispersible granules.
- the oral formulation may be modified release formulation which includes a sustained or slow release formulation, extended release, or immediate release or fast release formulation, phased release formulation or any other modified release profile which are well known in the art of pharmaceutical formulation preparations.
- the pharmaceutical composition comprises compound of formula II formulated into a lozenge.
- the invention further relates to methods of manufacturing lozenges wherein, one step comprises a granulation step.
- the granulation step may be a wet granulation and/or dry granulation.
- Stepl Dispensing all the required raw materials.
- Step-2 Granulation fluid: the active ingredient is dissolved in suitable solvent and or cosolvent.
- iii. Step-3 Sifting the excipients: binder, disintegrants, sweeting agent, glidants, anticaking agent, taste masking agent, preservative, penetration enhancer, bio availability enhancer, solubilizing agent, surfactant, co surfactant, flavoring agents through a sieve.
- Step-4 Dry mixing: The sifted step 3 raw materials is mixed.
- Step-5 Granulation: Granulated step 4 blend with step 2 granulating fluid.
- Step-6 Drying: The wet mass of step 5 is dried.
- Step-7 Sizing: The dried material of step 6, is sifted using a sieve.
- Step-8 Sifting: Extra-granular materials i.e. flavoring agents and lubricant is sieved.
- Step-9 Lubrication: The sifted material of step 8 is added to step 7 and blended.
- Step- 10 Compression: The lubricated blend of step 9 was compressed into lozenges with suitable punches on compression machine.
- the compounds of Formula I or Formula II or Formula III or Formula IV may be formulated for local administration.
- the formulation is a topical spray formulation.
- the spray formulation is a mucoadhesive and or bioadhesive formulation suitable for application to the skin or mucosal layer.
- the present disclosure in certain aspects is directed to a method of treating pain comprising the administration of a polymeric film forming spray formulation which is applied locally via the utilization of a spray device.
- the spray formulation is formulated such that it increases the permeability of Formula I or Formula II or Formula III or Formula IV through the mucosal layer or the skin after spray administration by a pump.
- a further unit dose of the topical polymeric film forming composition may be sprayed topical to the site of action about 5 hours after application of a first unit dose.
- the unit dose may be sprayed using a metered pump delivering device.
- Step 1 A solution A is prepared by adding the purified water into a compounding vessel and dissolving disintegrants, binder, preservative, lubricant, sweeting agent, agents which enable penetration, bio availability and retention time of the drug.
- Step 2 Solution B is prepared by adding solubilizing agent, self-emulsifying agent in compounding vessel and dissolving active ingredient. The solution A is added to Solution B and stirring continuously until the drug is completely dissolved. Volume is made up to with the remaining quantity of purified water.
- Step 3 The resultant solution is filtered under vacuum. This filtered solution is filled into glass vials and pump is crimped.
- the formula I, formula II, formula III or formula IV are examples of compounds of bupivacaine in ionic salt forms or a mixture of bupivacaine free base and glycerol fumarate fatty acid derivatives or mixture bupivacaine free base and glycerol succinate fatty acid derivatives.
- pain means pain due to tissue damage also referred as nociceptive pain, nerve damage also referred as neuropathic pain, or central sensation or generalized pain or a mixed type of pain.
- the pain can be either acute pain or chronic pain.
- radicular pain inflammatory pain, visceral pain, cancer pain, pain associated with stomatitis and mucositis, non-cancer pain, trauma pain, sport pain, surgical pain, wound pain, burn pain, musculoskeletal pain, postoperative pain, labor pains, pain associated with neurogenic bladder, ulcer, cankers and colitis, rest pain, surrounding mediated pain, main center mediated pain, chronic cephalalgia, migraine, sinus headache, tension headache, phantom limb pain, toothache, peripheral nerve injury and peripheral neuropathic pain such as post-herpetic neuralgia (PHN), pain due diabetic conditions such as painful peripheral diabetic neuropathy (pDPN), pain due to infections of open wounds, post-amputation pain, facial nerve problems such as Bell’s palsy, spinal nerve inflammation or compression, pain due to shingles, central nervous system disorders, such as multiple sclerosis or Parkinson’s disease, trigeminal neuralgia and accidents.
- PPN post-herpetic neuralgia
- pDPN painful
- neuropathy predominately includes peripheral neuropathy or central nervous injury such as PHP, DPN, lumbar or cervical radiculopathy, stenosis, tumor-related neuropathy, erythromelalgia, fibromyalgia, chemotherapy induced neuropathy, small fiber neuropathy, postoperative pain, phantom limb pain, chronic radiculopathy, multiple sclerosis pain, trigeminal neuralgia, post stroke pain, pain from spinal code injury, achondrogenesis, achondroplasia, achondroplastic dwarfism, acquired immunodeficiency syndrome (AIDS), HPV related rashes and pain, acute porphyrias, acute intermittant porphyria, acute shoulder neuritis, adrenomyeloneuropathy (AMN), adult dermatomyositis, amyotrophic lateral sclerosis, anal rectal malformations, arachnitis, arachnoiditis, arthritis, arthritis, arthritis
- nociceptive pain are pain due to damage or injury to bone, joint, muscle, skin or connective tissue. It predominately includes osteoarthritis, rheumatoid arthritis, tendonitis bursitis, ankylosing spondylitis, gout, neck and back pain with pathology, tumor related nociceptive pain, inflammatory bowel disease amongst others.
- central sensitization predominately includes fibromyalgia, irritable bowel syndrome, tension-types headaches, intestinal cystitis, pelvic pain, restless leg syndrome.
- the term “generalized pain” means widespread pain throughout the body with diffuse tenderness to palpation throughout body with absence of significant trigger points may be associated with depression or poor sleep conditions or due to central sensitization.
- the composition of the present invention is useful in treating radiation induced pain in mucositis and stomatitis patient.
- Inflammation of the mucosa is a common, dose limiting complication of high dose chemotherapy and radiotherapy in cancer patients. Server impairment of the patient's general condition is associated with subsequent bacterial superinfection.
- the prevalent bacterial pathogens species in mucositis is Scardovia spp., Lactobacillus spp., Streptococcus spp., Actinomyces spp., Staphylococcus spp., Enterococcus spp., usobacterium spp., Prevotella sp., Actinobacillus spp., and Candida spp. and others are observed in the oral cavity of radiotherapy, radio chemotherapy treated patients.
- Microbial infections are also very common in open wounds, cuts, surgical wound, burns rashes commonly found pathogens include Staphylococcus aureus, Escherichia coli, Staphylococcus epidermidis, S. aureus, Pseudomonas aeruginosa, Klebsiella pneumonia, Proteus mirabilis, Proteus vulgaris, S. mutans, A. actinomycetemcomitans, P. gingivalis, F. nucleatum, and S. gordonii and the fungal pathogens are Candida albicans, Aspergillus fumigatus and others.
- FFA Free Fatty Acids
- the prime target of FFA action is the cell membrane, where FFAs disrupt the electron transport chain and oxidative phosphorylation; also, it can interfere with cellular energy production, generation of peroxidation and auto-oxidation degradation products or direct lysis of bacterial cells.
- Medium-chain saturated fatty acids that lack a kinked structure can be packed more tightly and can reduce membrane fluidity and disrupt electron transport perhaps by restricting the movement of carriers within the membrane.
- the antibacterial effect of long chain unsaturated fatty acids were due to their inhibition of fatty acid biosynthesis.
- One of the biological activities of the free fatty acids (FFAs) is their ability to kill or inhibit the growth of pathogenic bacteria.
- compound of bupivacaine means salts, mixtures, prodrugs and derivatives of bupivacaine. Further, includes the compounds disclosed in the International Application No. PCT/IB 2017/052247, the contents of which are incorporated in its entirety herein by reference.
- the present invention discloses how the salts, derivatives and prodrugs of bupivacaine is formulated for effectively reducing the pain by binding to the intracellular portion of voltage-gated sodium channels and blocks sodium influx into nerve cells, which prevents depolarization thus stopping initiation or conduction of a pain signal can occur.
- present invention provides a compound which is more lipid soluble local anesthetic with anti- microbial properties associated with the naturally occurring fatty acids to reduce pathogenic microbial flora as well as enable sustained release of the drug to reduce the pain.
- the present invention provides pharmaceutical compositions or a formulations and methods thereof for providing pain relief by administering a dose of a local anesthetic formulation to the site for the treatment of acute or chronic pain, radiation induced pain, neuropathic pain or nociceptive pain or central sensation or generalized pain or a mixed type of pain as defined in the specification herein.
- the present invention provides pharmaceutical compositions for management/treatment of neuropathic pain or nociceptive pain or central sensation or generalized pain or a mixed type of pain.
- the present invention provides pharmaceutical compositions comprising local anesthetic or a pharmaceutically active salt, or a derivative or a mixturethereof.
- the local anesthetic or a pharmaceutically active salt thereof includes salts, derivatives and prodrugs of levo and dextro enantiomer of bupivacaine collectively called the compounds of bupivacaine in a racemic form or levobupivacaine.
- Levobupivacaine is the (S)-(-)-enantiomer of bupivacaine, with a longer duration of action and producing less vasodilation.
- Levobupivacaine and any pharmaceutically active salts thereof are included within the scope of the present invention.
- the instant invention provides pharmaceutical compositions comprising the compounds of bupivacaine (the active ingredient) selected from following chemical structures below.
- the composition is formulated based on the route of administration and is used in the pain management and treatment.
- compositions as disclosed comprises active ingredient sleeted from compounds of formula I [bupivacaine glyceryl dilauryl succinate] or formula II [bupivacaine glyceryl dilauryl fumarate/CLX-SYN-G161-Cl 1] or formula III [bupivacaine glyceryl dicaprylyl fumarate] or formula IV [bupivacaine glyceryl dicaprylyl succinate/CLX-SYN-G161-C01] along with at least one pharmaceutically acceptable excipient or carrier or vehicles or diluents.
- the pharmaceutical composition may comprise of formula I or formula II or formula III or formula IV along with one or more pharmaceutically acceptable excipients.
- Such a formulation is used in the preparation of medicament that can usedin the pain treatment and pain management.
- the present invention also provides suitable dosage forms comprising therapeutically effective amount of compound of Formula I or Formula II or Formula III or Formula IV for treatment of pain which can be administered locally, depot , infusion, spray, topical and/or orally.
- the present invention also provides pharmaceutical composition comprising 0.1% to 70% w/w local anesthetic and rest 30-99.9%w/w pharmaceutically acceptable excipients.
- the present invention provides easy, convenient, and patient friendly drug delivery system with better bio availability and long-lasting effect for treatment of pain.
- the compound of bupivacaine is formulated for oral administration such as chewable tablets, buccal tablets, chewing gum, oral dispersible tablet, mucoadhesive tablet, patches, tablets, cachets, lozenges, powder-based lozenges, syrup-based lozenges, granulated lozenges, pastilles and dispersible granules or any other oral administration formulation.
- the oral formulation can be a sustained or slow-release formulation or immediate or fast release formulation, phased release formulation or any other modified release profile know in the art of pharmaceutical formulation.
- the sustained-release composition is preferably formulated to provide sustained release of the compound of bupivacaine over time period of at least 1, 2, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 55, 60, 70, 80 minutes, 90 minutes or at least 100 minutes, for example up to about 2 hours, 3 hours, 4 hours, or 5 hours or hours or 10 hours. All of these values can be permutated to represent upper and lower limits of ranges of release time, for example the range can be 10 to 60 minutes.
- sustained-release composition is preferably formulated to provide sustained release of the compound of bupivacaine at least for 20 minutes, at least for 40 minutes, at least for 60 minutes, at least for 80 minutes, at least for 100 minutes or at least up to about 2 hours, at least up to 4 hours, at least up to 8 hours, or at least up to 10 hours.
- a lozenge formulation contains 1 to 80 mg compound of Formula I or Formula II or Formula III or Formula IV equivalent to bupivacaine in an active form, in an embodiment of the invention and is suitable for use over extended periods.
- the pharmaceutical composition comprises compound of formula II [bupivacaine glyceryl dilauryl fumarate or CLX-SYN-G161-C11] is formulated into a lozenge.
- Formula I or Formula II or Formula III or Formula IV thereof is preferably present in an amount of 5 mg to 2 gm or 5 mg tolOOmg, preferably 5 to 75 mg, for example 5 mg, 10 mg, 25 mg or 50 mg, 60mg, 65mg, 70mg, 71mg, 72mg, 73mg or 75mg per unit dosage form.
- the invention further relates to methods of producing lozenges wherein one step comprises a granulation step.
- the granulation step may be a wet granulation and/or dry granulation.
- the invention in another embodiment, relates to a method for preparing the lozenge formulation.
- the method comprises: xi. Stepl: Dispensing all the required raw materials.
- the lozenges prepared using the above method can last even longer in the mouth and seem not so dry for the patient when they suck them.
- the compound of bupivacaine may be formulated for local and or topical administration.
- the formulation may be a spray formulation.
- the present disclosure in certain aspects is directed to a method of treating pain comprising the administration of a polymeric film forming spray formulation which is applied locally or topically to the target site via the utilization of a spray device.
- the compound of bupivacaine thereof is preferably present in an amount of 5 mg to 2 gm or5 mg to 100 mg, in a preferred embodiment 5 to 75 mg, or preferably 5 mg, 10 mg, 25 mg or 50 mg, 60 mg, 65 mg, 70 mg, 71 mg, 72 mg, 73 mg or 75 mg per ml of the spray.
- the composition is formulated as a liquid dosage form considering compounds of formula I, formula II, formula III or formula IV characteristics and route of administration.
- the excipients are selected based on dosage form, physicochemical characteristics of active ingredient, stability, and compatibility issues.
- the formulation is packed in a sprayable device to deliver uniform dose from the bottle.
- the device comprises of an actuator with long cannula which enables to deliver the product to the affected area.
- the composition may have one or more polymer in the formulation to form a film upon administration and for sustained release of the active ingredient via compound of bupivacaine.
- Preservative and sweetening agents is included to increase microbiological stability and dose adherence by the patient.
- the invention in another embodiment relates to a method for preparing a spray formulation comprising: iv. Step 1: A solution A is prepared by adding the purified water into a compounding vessel and dissolving any excipient such as disintegrants, binder, preservative, lubricant, sweeting agent, agents which enable penetration, bio availability, and retention time of the drug. v. Step 2: Solution B is prepared by adding solubilizing agent, self-emulsifying agent or any other excipient in compounding vessel and dissolving active ingredient. The solution A is added to Solution B and stirring continuously until the drug is completely dissolved. Volume is made up to with the remaining quantity of purified water. vi. Step 3: The resultant solution is filtered under vacuum. This filtered solution is filled into glass vials and pump is crimped.
- a solution A is prepared by adding the purified water into a compounding vessel and dissolving any excipient such as disintegrants, binder, preservative, lubricant, sweeting agent, agents which enable penetration, bio availability
- compositions as disclosed comprises compounds of formula I [bupivacaine glyceryl dilauryl succinate] or formula II [bupivacaine glyceryl dilauryl fumarate/CLX-SYN-G161-Cl l] or formula III [bupivacaine glyceryl dicaprylyl fumarate] or formula IV [bupivacaine glyceryl dicaprylyl succinate/CLX-SYN-G161-C01] along with at least with one or more pharmaceutical excipients which has high safety profile, slow release, better permeability, long lasting effect and low toxicity.
- the pharmaceutical excipients examples include, anti-adherents, binders, coatings, penetration enhancers, solubilizer, surfactant, propellant agents, dispensing agents, colors, disintegrants, flavors, glidants, lubricants, preservatives, sorbents, sweeteners, vehicles.
- present invention discloses a pharmaceutical composition formulated into solid and liquid formulation for easy and convenient administration.
- a pharmaceutical composition for special patients’ category such as geriatric and pediatric suffering from pain.
- the excipients used are suitable for spray formulation for pressurized packages, pressurized dosage forms such as NDDS for dispensing the compounds of the present invention to the systemic circulation as well as the local action is disclosed.
- the nonlimiting examples of such excipients includes antioxidants, emollients, solvents and co-solvents, humectants, antifoaming agents, surfactants, film forming agents, preservatives and wetting agents.
- the drug carrier may be a penicillin bottle, an ampule, a fillable injector, a spray bottle, or an aerosol bottle. Further, the system is plugged with a stopper and sealed with a cover to obtain the sustained-release of the active ingredient; wherein, in the case of the aerosol bottle, the stock solution is added first and the bottle is then charged with a propellant and sealed.
- present invention is directed to a topical polymeric film forming composition, comprising compounds of bupivacaine dispersed in a solvent together with a film forming polymer, which also acts as a permeation enhancer and improves or enhances the bio availability of the drug and release the compound of bupivacaine in sustained manner.
- the composition will have a lubricant, polymeric vehicle, preservative, sweeting agent and other excipient suitable for the spray formulation.
- This formulation being capable of being sprayed as a unit dose onto the site of pain via the use of a pump spray to provide droplets having a diameter from about 0.5 to about 1000 microns.
- the topical polymeric film forming composition when sprayed releases about 0.01% to about 50% of the active agent within the initial 1 to 5 hours of its application.
- the permeation enhancers used for the spray formulation is selected from a group comprising isopropyl myristate, oleic acid, capric acid, lauric acid, Lauric acid, propylene glycol, diethylene glycol mono ethyl ether, methyloleate, lysophosphatidylcholine, phosphatidylcholine, cyclodextrin, dextran sulfate, polysorbate 80, ethanol, n - methyl - 2 - pyrrolidone, sodium lauryl sulfate, polyoxyl cetostearyl ether, polyoxyl oleyl ether, polyoxyl lauryl ether or a combination thereof and the like.
- the formulation provides a compound of Formula I or Formula II or Formula III or Formula IV with dose ranging from about 5 mg to 2 gm or 5 mg to about 100 mg, or from about 1 mg to about 75 mg compound of bupivacaine, sprayed as a unit dose onto the skin, to provide a film surface area from about 1 cm 2 to about 40 cm 2 per spray.
- the unit dose may be from 1 to about 20 sprays per application of the unit dose onto the surface.
- the active agent comprises from 1 to 75 mg of formula II preferably 70mg or 71 mg or 72 mg or 73 mg or 74 mg or 75mg.
- the unit dose containing the bupivacaine may be, e.g., 73 mg, and the dose may be administered as 73 mg/ml per spray.
- present invention provides a method of treating different types of pains, by spraying a unit dose of a topical polymeric film forming composition comprising a therapeutically effective amount of a local anesthetic (one of the compound of bupivacaine active salt forms or mixtures, exemplified in formula II) dispersed in a suitable solvent together with a film forming polymer in an amount from about 2% to about 80%, by weight or 2% to 70% by weight (for examples 70% by weight) along with other excipient such as lubricant, polymeric vehicle, preservative and sweeting agent.
- a local anesthetic one of the compound of bupivacaine active salt forms or mixtures, exemplified in formula II
- a film forming polymer in an amount from about 2% to about 80%, by weight or 2% to 70% by weight (for examples 70% by weight) along with other excipient such as lubricant, polymeric vehicle, preservative and sweeting agent.
- the formed film is sufficiently stable to provide a drug release to up to 24 hours.
- the polymeric solution is sprayed local to the site of action as a liquid and forms an almost invisible film in situ by volatile solvent evaporation.
- the film may be peelable and/or non-peelable in nature.
- the film is breathable, and microporous. It may be bioadhesive and mucoadhesive.
- the film may be non-greasy and non-sticky.
- the pharmaceutical composition of present invention comprises local anesthetic along with pharmaceutically acceptable excipients selected from ethanol, Kolliphor RH40, PVP K30, sodium hyaluronate, sodium benzoate, povidone, mannitol, colloidal silicon dioxide, croscarmellose sodium, saccharin sodium dehydrate, citric acid monohydrate, xylitol, peppermint flavor, water and labrasol.
- pharmaceutically acceptable excipients selected from ethanol, Kolliphor RH40, PVP K30, sodium hyaluronate, sodium benzoate, povidone, mannitol, colloidal silicon dioxide, croscarmellose sodium, saccharin sodium dehydrate, citric acid monohydrate, xylitol, peppermint flavor, water and labrasol.
- the lozenge composition of present invention comprises bupivacaine glyceryl dilauryl fumarate, povidone, mannitol, colloidal silicon dioxide, croscarmellose sodium, caprylocaproyl polyoxylglycerides 8, saccharin sodium dihydrate, citric acid monohydrate, peppermint flavor, magnesium stearate, sodium benzoate and dehydrated alcohol.
- the lozenge composition includes bupivacaine glyceryl dilauryl fumarate 9.70% (w/w), povidone 6.70%(w/w), mannitol 74.10% (w/w), colloidal silicon dioxide 6.70%(w/w), croscarmellose sodium 0.10%(w/w), saccharin sodium dihydrate 0.30 %(w/w), citric acid monohydrate 0.50%(w/w), peppermint flavor 0.70%(w/w), magnesium stearate 1.20%(w/w) and dehydrated alcohol.
- the lozenge composition includes bupivacaine glyceryl dilauryl succinate 9.70% (w/w), povidone 6.70%(w/w), mannitol 74.10% (w/w), colloidal silicon dioxide 6.70%(w/w), croscarmellose sodium 0.10%(w/w), saccharin sodium dihydrate 0.30 %(w/w), citric acid monohydrate 0.50%(w/w), peppermint flavor 0.70%(w/w), magnesium stearate 1.20%(w/w) and dehydrated alcohol.
- the lozenge composition includes bupivacaine glyceryl dicapryl fumarate 9.70% (w/w), povidone 6.70%(w/w), mannitol 74.10% (w/w), colloidal silicon dioxide 6.70%(w/w), croscarmellose sodium 0.10%(w/w), saccharin sodium dihydrate 0.30 %(w/w), citric acid monohydrate 0.50%(w/w), peppermint flavor 0.70%(w/w), magnesium stearate 1.20%(w/w) and dehydrated alcohol.
- the lozenge composition includes bupivacaine glyceryl dicapryl succinate 9.70% (w/w), povidone 6.70%(w/w), mannitol 74.10% (w/w), colloidal silicon dioxide 6.70%(w/w), croscarmellose sodium 0.10%(w/w), saccharin sodium dihydrate 0.30 %(w/w), citric acid monohydrate 0.50%(w/w), peppermint flavor 0.70%(w/w), magnesium stearate 1.20%(w/w) and dehydrated alcohol.
- the spray formulation for topical or local application include bupivacaine glyceryl dilauryl fumarate, caprylocaproyl polyoxylglycerides 8, sodium hyaluronate, PVP K30, sodium benzoate, xylitol, and purified water.
- the spray formulation for topical or local application include bupivacaine glyceryl dilauryl fumarate 7.3% (w/w), caprylocaproyl polyoxylglycerides 8 70 % (w/w), sodium hyaluronate 0.1% (w/w), PVP K30 0.1% (w/w), sodium benzoate 0.1% (w/w), xylitol 0.1% (w/w) and purified water.
- the spray formulation for topical or local application include bupivacaine glyceryl dilauryl succinate 7.3% (w/w), caprylocaproyl polyoxylglycerides 8 70 % (w/w), sodium hyaluronate 0.1% (w/w), PVP K30 0.1% (w/w), sodium benzoate 0.1% (w/w), xylitol 0.1% (w/w) and purified water.
- the spray formulation for topical or local application include bupivacaine glyceryl dicapryl succinate 7.3% (w/w), caprylocaproyl polyoxylglycerides 8 70 % (w/w), sodium hyaluronate 0.1% (w/w), PVP K30 0.1% (w/w), sodium benzoate 0.1% (w/w), xylitol 0.1% (w/w) and purified water.
- the spray formulation for topical or local application include bupivacaine glyceryl dicapryl fumarate 7.3% (w/w), caprylocaproyl polyoxylglycerides 8 70 % (w/w), sodium hyaluronate 0.1% (w/w), PVP K30 0.1% (w/w), sodium benzoate 0.1% (w/w), xylitol 0.1% (w/w) and purified water.
- present invention discloses one or more dosage form suitable for management and treatment of pain.
- composition is formulated into dosage forms such as lozenge/troches, tablets, chewable tablets, buccal tablets/pastes and sublingual drops/sprays, capsule, mucoadhesive patches, suspension, dispersion, gels, cream, ointments, sprays, dermal patches, transcutaneous patches, implant and others.
- dosage forms such as lozenge/troches, tablets, chewable tablets, buccal tablets/pastes and sublingual drops/sprays, capsule, mucoadhesive patches, suspension, dispersion, gels, cream, ointments, sprays, dermal patches, transcutaneous patches, implant and others.
- Other well-known pharmaceutical formulation known in the art can be suitable adopted for formulating the compounds of present invention.
- present invention discloses a pharmaceutical composition with modified release criteria such as extended/prolonged release formulation, Immediate release, sustained release, delay ed/lapsed release formulation and or multiphasic release formulation such as (biphasic or pulsatile), targeted release and immediate release.
- the formulation can be a combination of immediate and sustained release, or it can be immediate and lapsed release formulation.
- the pharmaceutical composition is formulated to releases sufficient therapeutic does of compound of the invention from the composition immediately within 1, 2, 5, 10, 15, 20, 30, 60 minutes of oral administration.
- sustained formulations releases the compounds of the invention over a time period for example up to 5minutes, 25 minutes, 55 minutes, preferably up to 60 minutes, up to 90 minutes or up to 100 minutes, up to 5 hours or up to 10 hours or up to 24 hours or up to 48 hours.
- present invention provides a topical formulation containing compound of the present invention, and a vehicle.
- vehicle usually contains water, oil, alcohol or propylene glycol mixed with preservatives, emulsifiers, absorption promoters and fragrances.
- present invention provides a film forming systems comprising the compound of the present invention for topical and transdermal drug delivery.
- the pharmaceutical composition along with biodegradable polymer (s), and the active ingredients may comprise surfactants, excipients, or other ingredients or combinations thereof.
- biodegradable polymer includes poly (lactic acid coglycolide) (or poly (lactic acid coglycolic acid)) or poly (orthoester), D-lactide, D, L-lactide, L- lactide, D, L-lactide-capro lactone, and D, L- lactide coglycolide cocaprolactone or combinations thereof.
- the depot may comprise a biodegradable biopolymer that can provide immediate or sustained release of active ingredient.
- biopolymers suitable for sustained release include, poly (a-hydroxy acid), poly (lactide coglycolide) (PLGA), polylactide (PLA), polyglycolide (PG), poly (a-hydroxy acid ) Polyethylene glycol (PEG) conjugate, polyorthoester (POE), polyaspirin, polyphosphagen, collagen, starch, gelatinized starch, hyaluronic acid, chitosan, gelatin, alginate, albumin, fibrin, a- tocopheryl acetate, d -Vitamin E analogs such as alpha tocopheryl succinate, D, L-lactide, or L- lactide, -caprolactone, dextran, vinyl pyrrolidone, polyvinyl alcohol (PVA), PVA-g-PLGA, PEGT-PBT
- LD50 values of gelucire 44/14, labrasol, and labrafil M1944CS polyvinyl alcohol, polyvinyl acetate, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, dextrans, hyaluronic acid, cyclodextrins, polysaccharide polymers, polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer or a combination of these is included.
- the surfactants useful for forming micelles include, but are not limited to, potassium laurate, sodium octane sulfonate, sodium decane sulfonate, sodium dodecane sulfonate, sodium lauryl sulfate, docusate sodium, decyltrimethylammonium bromide, dodecyltrimethylammonium bromide, tetradecyltrimethylammonium bromide, tetradecyltrimethyl-ammonium chloride, dodecylammonium chloride, polyoxyl 8 dodecyl ether, polyoxyl 12 dodecyl ether, nonoxynol 10 and nonoxynol 30.
- Micelle formulations can be used in the present invention either by incorporation into the reservoir of a topical or transdermal delivery system, or into a formulation to be applied to the body surface.
- present invention envisages a liposome drug delivery system.
- the liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations.
- cationic liposomes are N-[l- 2,3-dioleyloxy)propyl]-N,N,N-triethylammonium liposomes are available under the tradename Lipofectin®.
- anionic and neutral liposomes are Avanti Polar Lipids or can be prepared using materials like phosphatidyl choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline, dioleoylphosphatidyl glycerol, dioleoylpho shat idyl ethanolamine, among others. These materials can also be mixed with N-[l-23-dioleyloxy)propyl]-N,N,N- triethylammonium (DOTMA) in appropriate ratios.
- DOTMA N-[l-23-dioleyloxy)propyl]-N,N,N- triethylammonium
- present invention envisages microspheres, as the drug delivery systems.
- Microspheres essentially encapsulate a drug or drug containing formulation. They are generally, although not necessarily, formed from lipids, preferably charged lipids such as phospholipids. Preparation of lipidic microspheres is well known in the art and described in the pertinent texts and literature.
- the composition is formulated into chewy or hard or caramel based lozenge, pastilles, troches, soft lozenge, center or liquid filled lozenge, power based lozenge, compressed lozenge, syrup based lozenge, granulated lozenge, buccal and sublingual tablets.
- the lozenges formulation of the invention will increase bio availability, reducing gastric irritation and increase onset of action.
- Lozenges dosage forms are easy to administer for geriatric and pediatric patients who can’t swallow tablets formulation. This formulation will help to keep the drug in contact to the oral cavity for longer time.
- the oral administration formulation may be classified into rapidly disintegrating formulations for which the release of an active component from the formulations is not particularly controlled and release-controlled formulations for which the release is controlled according to the purposes by adjusting the dosage design and production method.
- the composition can be a sustained release formulations wherein the release rate, release time and release site of an active component from the formulation is controlled with the purpose of reduction in the frequency of administration or reduction of side effects.
- the sustained release formulation may be generally produced by using an appropriate agent for sustained release.
- the carrier material for lozenge preparation includes sugar such as sucrose, dextrose, etc.
- sugar-free products including sugar-free medications.
- Pharmaceutical manufacturers have attempted to find alternative carrier bases in order to provide sugar-free lozenges.
- One such alternative carrier is a polyhydric alcohol such as xylitol.
- Polyhydric alcohols are considered as a viable alternative because they provide a sweet taste will mask the bitter taste of many medicinal agents.
- Lozenges made from polyhydric alcohols do suffer from one serious disadvantage. They dissolve very rapidly when placed in the oral cavity. For example, a lozenge made from a xylitol-based carrier will dissolve completely within approximately 3 minutes of administration. Other polyhydric alcohols such as sorbitol or mannitol will also dissolve within 3 minutes of administration. Thus, the medicinal agents are released so rapidly that a large percentage of the dose is washed into the patients alimentary canal rather than having an opportunity to come in contact with the tissues of the oral cavity which are under treatment. Thus, it would be a valuable contribution to the art to produce polyhydric alcohol based lozenges having slower rates of dissolution within the oral cavity.
- non-limiting examples of excipients for preparing a compressed powder lozenge or compressed granulated lozenge, cast lozenge includes at least one diluents, at least one fillers, at least one glidants, at least one lubricants, at least one binders, at least one preservatives, at least one artificial or natural sweeteners or and at least one aroma/flavoring compounds [00105]
- Non-limiting examples of diluents, fillers or binder, disintegrants, sweeting agent, super disintegrants, anticaking agent absorbent, taste masking agent, antioxidant, solvent, co-solvent and other excipient are selected from the group consisting of mannitol, celluloses, lactose, starches, calcium salts, di calcium phosphate, calcium sulfate, polyvinylpyrrolidine, gelatine, sugars and sugar alcohols, microcrystalline cellulose, polyvinylpyrrolidine, polar solvent may be an organic solvent.
- sugar- free vehicles includes mannitol, sorbitol, polyethylene glycol (PEG) 6000 and 8000 and sugar based vehicles include- sucrose, maltose, lactose, dextrose.
- aroma/flavoring agent compounds can be either natural or synthetic aromatic compounds including but not limited to fruit aromas, powders including but not limited to vanillin and menthol, peppermint or pharmaceutical acceptable essential oils, non-limiting examples of sweeteners includes, nonsugar sweetening agents such as aspartame, sorbitol, xylitol, isomalt, saccharin, sodium saccharin, calcium saccharin, sucralose, acesulfame-K, steviol, steviosin, mannitol, erythritol, lactitol, and sugar sweetening agents selected from the group consisting sucrose, fructose, or dextrose.
- compositions are formulated as cast lozenges comprising of at least one base selected fructo-oligosaccharides, crystalline sugar, candy base, isomalt or stevia; at least one aromas selected natural aroma, essential oils such as citrus, mint oils, terpenes and sesquiterpenes, organic acids, alcohols, aldehydes, liquorice powder, menthol, peppermint oil or any fruit flavors, at least one taste enhancing ingredients such as saccharose, glutamic acid, E621 mo no sodium glutamate, MSG, E622 monopotassium glutamate, E623 calcium diglutamate, E625 Magnesium diglutamate); guanylic acid (a ribonucleotide) and its salts (E626 guanylic acid, E627 disodium guanylate, sodium guanylate, E628 dipotassium guanylate, E629 calcium guanylate); E630 inosinic acid, E631
- the lozenge formulation contains compound bupivacaine in an amount of 5 mg to 2 gm per oral dosage form such as lozenge, tablet, capsule and others.
- the lozenge formulation contains compound of formula I or formula II or formula III or formula IV in an amount of 5 mg to 2 gms per oral dosage form.
- active ingredients and excipients are mixed to form a sprayable topical formulation.
- the compounds of the invention can be generally formulated into sprays (oral, topical, thin-film, peel-forming, encapsulated, polymer based) by selecting one or more compounds of the invention with at least one pharmaceutically acceptable excipient.
- excipients includes: a) solvents/ vehicles example includes organic solvents (acetone, acetic acid, acetonitrile, benzene, carbon tetrachloride, methylene chloride etc.) and inorganic solvents(liquid ammonia, liquid sulfur dioxide, sulfuryl chloride and sulfuryl chloride fluoride, phosphoryl chloride, dinitrogen tetroxide, antimony trichloride, bromine pentafluoride, hydrogen fluoride, pure sulfuric acid other well known in the art; b) Co-solvents example includes propylene glycol, glycerol, ethanol, low molecular weight PEGs; wetting agents/ surfactants polysorbates, sorbitan esters anionic (e.g., sodium dodecyl sulfate), cationic (e.g., trialkylammonium), zwitterionic (e.g., glycine and proteins) and nonionic (e.g.,
- emollients non-limiting example includes occlusive emollients such as lanolin, emulsifying ointment, and liquid paraffin; d) preservatives example includes acidic types are phenol, benzoic acid, boric acid, chloro-cresol, 9-phenyl phenol, alkyl esters of para-hydroxybenzoic acid, sorbic acid, and their respective salts, neutral preservatives include chlorobutanol, benzyl alcohol, betaphenylethyl alcohol, methylparaben, ethylparaben, butylparaben, propylparaben, sodium benzoate, benzoic acid, or a mixture of these parabens with phenyl e
- present invention discloses a transdermal patch wherin the drug reservoir comprises a polymeric matrix of a pharmaceutically acceptable adhesive material that serves to affix the system to the skin during drug delivery.
- suitable adhesive materials include, but are not limited to, the following: polyethylenes; polysiloxanes; polyisobutylenes; polyacrylates; polyacrylamides; polyurethanes; plasticized ethylene-vinyl acetate copolymers; and tacky rubbers such as polyisobutene, polybutadiene, polystyrene- isoprene copolymers, polystyrene-butadiene copolymers, and neoprene (polychloroprene).
- Preferred adhesives are polyisobutylenes.
- the reservoir may be a hydrogel reservoir.
- Hydrogels are macromolecular networks that absorb water and thus swell but do not dissolve in water.
- Hydrogels comprise of crosslinked hydrophilic polymers such as a polyurethane, a polyvinyl alcohol, a polyacrylic acid, a polyoxyethylene, a polyvinylpyrrolidone, a poly(hydroxyethyl methacrylate) (poly(HEMA)), or a copolymer or mixture thereof.
- Particularly preferred hydrophilic polymers are copolymers of HEMA and polyvinylpyrrolidone.
- the material used for the backing layer are generally derived from synthetic polymers (e.g., polyester, polyethylene, polypropylene, polyurethane, polyvinylidine chloride, and polyether amide), natural polymers (e.g., cellulosic materials), or macroporous woven and nonwoven materials.
- synthetic polymers e.g., polyester, polyethylene, polypropylene, polyurethane, polyvinylidine chloride, and polyether amide
- natural polymers e.g., cellulosic materials
- macroporous woven and nonwoven materials e.g., polyester, polyethylene, polypropylene, polyurethane, polyvinylidine chloride, and polyether amide
- the active ingredient is the compound of bupivacaine, more specifically formula II (Bupivacaine glyceryl dilauryl fumarate), is formulated as lozenges to be dissolved slowly in the oral cavity. Each lozenge contains 73.08 mg of Bupivacaine glyceryl dilauryl fumarate.
- the pharmaceutically acceptable excipients or the inactive ingredients are Mannitol, Povidone, Croscarmellose sodium, Citric acid monohydrate, Saccharin sodium dihydrate, Silicon dioxide, Peppermint flavor 501500 TP0504, Magnesium stearate and dehydrated alcohol.
- the qualitative composition for product formulation was provided in Tables 1 and 2.
- Table 1 Composition of Bupivacaine dilauryl glyceryl fumarate Lozenges
- Formulation development was initiated with the inactive ingredients selected based on the literature and prior use in similar dosage form.
- Various polymers and disintegrant at different concentrations were evaluated for dissolution profile and impurity profile of drug product.
- Step-1 Dispensing: Dispensed all the required raw materials using a calibrated weighing balance.
- Step-2 Granulation fluid: Bupivacaine glyceryl dilauryl fumarate was dissolved in 24 g (75% of total alcohol required for batch manufacturing) of dehydrated alcohol under stirring.
- Step-3 Sifting: Sifted povidone, mannitol, colloidal silicon dioxide, saccharin sodium dihydrate, citric acid monohydrate, croscarmellose sodium through #30 ASTM sieve.
- Step-4 Dry mixing: The sifted step 3 raw materials were mixed for 15 minutes.
- Step-5 Granulation: Granulated step 4 blend with step 2 granulating fluid. Rinsed the container with remaining 6g of dehydrated alcohol and used as granulating solution.
- Step-6 Drying: The wet mass of step 5 was dried at 45°C for 60 min.
- Step-7 Sizing: The dried material of step 6, were sifted using #30 ASTM sieve.
- Step-8 Sifting: Extra-granular materials i.e., peppermint flavor and magnesium stearate were passed through #60 ASTM sieve
- Step-9 Lubrication: The sifted material of step 8 was added to step 7 and blended for 5 minutes.
- Step- 10 Compression: The lubricated blend of step 9 was compressed into lozenges with suitable punches on compression machine.
- Step- 11 Packaging: The compressed lozenges were packed along with silica gel bags, in 40 cc HDPE Bottle / 33 mm CRC at 15 lozenges per bottle.
- the composition is formulated as a liquid dosage form considering compound of bupivacaine characteristics and route of administration.
- the excipients are selected based on dosage form, physicochemical characteristics of active ingredient, stability and compatibility issues.
- the device comprises of a actuator with long cannula which enables to deliver the product to the affected area.
- the composition may have one or more polymer in the formulation to form a film upon administration and for sustained release of the active ingredient via compound of bupivacaine.
- Preservative and sweetening agents is included to increase microbiological stability and dose adherence by the patient.
- Table 8 Composition of Bupivacaine dilauryl glyceryl fumarate oral spray
- Step 1 Solution A is prepared with the addition of 25% of batch quantity of purified water into a compounding vessel and dissolving PVP K-30, sodium benzoate sodium hyaluronate, and Xylitol.
- Step 2 Solution B is prepared with the addition of batch quantity of Caprylocaproyl polyoxylglycerides 8 in compounding vessel and dissolving Bupivacaine dilauryl glyceryl fumarate (CLX-SYN-G161-C11) for 1 hour. The solution A is added to Solution B and stirring is continued until the drug is completely dissolved. Volume is made up to batch size with the remaining quantity of purified water
- Step 3 The resultant solution is filtered using 0.45 p PTFE filter under vacuum. This filtered solution is filled into 50 cc USP type-1 glass vials with fill volume of 50 ml and pump is crimped. [00130] Container Closure Systems for Spray formulation:
- Table 10 Composition of bupivacaine dilauryl glyceryl fumarate
- Table 11 Composition of bupivacaine dilauryl glyceryl fumarate
- Table 12 Composition of bupivacaine dilauryl glyceryl fumarate
- the effective dosages and sites of administration of pharmaceutical composition of the present invention can be at the site or adjacent to the sites of pain to provide the much-needed relief.
- the composition can be administered once a day, for quick and temporary relief from pain, or more frequently, in a day, to maintain pain relief over a longer period.
- the composition is applied once or more than once topically to a site of pain or adjacent that region.
- the dosing is applied to the region or area of pain in order to effect pain relief while avoiding the side effects associated with systemic delivery.
- the compounds are applied such that the dosage is sufficient to provide an effective dose in the painful areas to eliminate pain and other unpleasant sensations associated with such pain.
- compositions according to the present disclosure when administered by spraying is done using commercially available spray devices and especially metered spray devices for treating pain.
- the composition can be administered intradermally, using, for example, an insulin syringe. Care is taken to administer the smallest dose possible, and in all cases, topical or intradermal, care should be taken to avoid systemic levels or local toxicity.
- the composition can applied topically to a site of pain or adjacent to that region using transdermal patches to effect pain relief while avoiding the side effects associated with systemic delivery.
- the compounds are applied such that the dosage is sufficient to provide an effective dose in the painful areas to eliminate pain and other unpleasant sensations associated with such pain.
- the formulations can be used to treat nociceptive pain, neuropathic pain, or central sensation or generalized pain or a mixed type of pain and others as disclosed in this specification.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL302900A IL302900A (en) | 2020-11-21 | 2021-11-20 | Pharmaceutical compositions for use in the management and treatment of pain |
KR1020237020643A KR20230110562A (en) | 2020-11-21 | 2021-11-20 | Pharmaceutical compositions for use in pain management and treatment |
MX2023005988A MX2023005988A (en) | 2020-11-21 | 2021-11-20 | Pharmaceutical compositions for use in the management and treatment of pain. |
AU2021381054A AU2021381054A1 (en) | 2020-11-21 | 2021-11-20 | Pharmaceutical compositions for use in the management and treatment of pain |
CA3195406A CA3195406A1 (en) | 2020-11-21 | 2021-11-20 | Pharmaceutical compositions for use in the management and treatment of pain |
EP21894166.4A EP4225289A1 (en) | 2020-11-21 | 2021-11-20 | Pharmaceutical compositions for use in the management and treatment of pain |
JP2023531124A JP2024500638A (en) | 2020-11-21 | 2021-11-20 | Pharmaceutical compositions for use in pain management and treatment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202041050763 | 2020-11-21 | ||
IN202041050763 | 2020-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022107084A1 true WO2022107084A1 (en) | 2022-05-27 |
Family
ID=81708497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2021/060776 WO2022107084A1 (en) | 2020-11-21 | 2021-11-20 | Pharmaceutical compositions for use in the management and treatment of pain |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4225289A1 (en) |
JP (1) | JP2024500638A (en) |
KR (1) | KR20230110562A (en) |
AU (1) | AU2021381054A1 (en) |
CA (1) | CA3195406A1 (en) |
IL (1) | IL302900A (en) |
MX (1) | MX2023005988A (en) |
WO (1) | WO2022107084A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010080831A1 (en) * | 2009-01-06 | 2010-07-15 | Jie Zhang | Method of treating neuropathic pain |
US8119694B2 (en) * | 2008-08-15 | 2012-02-21 | Arcion Therapeutics, Inc. | High concentration local anesthetic formulations |
US20180221358A1 (en) * | 2011-04-29 | 2018-08-09 | Moberg Pharma Ab | Pharmaceutical compositions comprising a local anaesthetic such as bupivacaine for local administration to the mouth or throat |
-
2021
- 2021-11-20 WO PCT/IB2021/060776 patent/WO2022107084A1/en active Application Filing
- 2021-11-20 EP EP21894166.4A patent/EP4225289A1/en active Pending
- 2021-11-20 MX MX2023005988A patent/MX2023005988A/en unknown
- 2021-11-20 AU AU2021381054A patent/AU2021381054A1/en active Pending
- 2021-11-20 KR KR1020237020643A patent/KR20230110562A/en unknown
- 2021-11-20 CA CA3195406A patent/CA3195406A1/en active Pending
- 2021-11-20 IL IL302900A patent/IL302900A/en unknown
- 2021-11-20 JP JP2023531124A patent/JP2024500638A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8119694B2 (en) * | 2008-08-15 | 2012-02-21 | Arcion Therapeutics, Inc. | High concentration local anesthetic formulations |
WO2010080831A1 (en) * | 2009-01-06 | 2010-07-15 | Jie Zhang | Method of treating neuropathic pain |
US20180221358A1 (en) * | 2011-04-29 | 2018-08-09 | Moberg Pharma Ab | Pharmaceutical compositions comprising a local anaesthetic such as bupivacaine for local administration to the mouth or throat |
Also Published As
Publication number | Publication date |
---|---|
JP2024500638A (en) | 2024-01-10 |
MX2023005988A (en) | 2023-06-07 |
IL302900A (en) | 2023-07-01 |
CA3195406A1 (en) | 2022-05-27 |
AU2021381054A1 (en) | 2023-05-25 |
EP4225289A1 (en) | 2023-08-16 |
KR20230110562A (en) | 2023-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11045464B2 (en) | Parenteral formulations of dopamine agonists | |
AU2007298814B2 (en) | Galenic form for the trans-mucosal delivery of active ingredients | |
EP1511481B1 (en) | Ophthalmological use of roflumilast for the treatment of diseases of the eye | |
US10201519B2 (en) | Stabilized pediatric suspension of carisbamate | |
US10137132B2 (en) | Parenteral formulations of dopamine agonists | |
AU775112B2 (en) | Compositions and methods comprising morphine gluconate | |
KR20090042956A (en) | Ophthalmic percutaneous absorption type preparation | |
US20210401824A1 (en) | Parenteral Formulations of Dopamine Agonists | |
WO2019038586A1 (en) | Pharmaceutical composition of melatonin | |
EP3915547A1 (en) | Transmucosal dosage forms of remdesivir | |
US8889663B2 (en) | Formulation for oral transmucosal administration of lipid-lowering drugs | |
US20160296463A1 (en) | Rapidly disintegrating formulations and methods thereof | |
JPH04275235A (en) | Absorption-promoting agent and external preparation containing the same | |
US20160136089A1 (en) | Unit dose formulations of ketorolac for intranasal administration | |
WO2022107084A1 (en) | Pharmaceutical compositions for use in the management and treatment of pain | |
WO2019161470A1 (en) | Pharmaceutical composition in the form of an aqueous suspension and use of a pharmaceutical composition in the form of an aqueous suspension | |
WO2016137411A1 (en) | Topical spray composition comprising ibuprofen and lidocaine | |
US20150141473A1 (en) | Pharmaceutical dosage forms of tizanidine and administration routes thereof | |
KR20210154964A (en) | Orally disintegrating tablets comprising glycopyrrolate and methods for increasing bioavailability | |
MX2011007814A (en) | New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative. | |
KR20060117572A (en) | Release controlled preparations containing aceclofenac | |
WO2017212409A1 (en) | A novel pharmaceutical composition of a lipid lowering compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21894166 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3195406 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021894166 Country of ref document: EP Effective date: 20230508 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023531124 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2021381054 Country of ref document: AU Date of ref document: 20211120 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023009822 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20237020643 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112023009822 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230522 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |